Kromek Group plc designs, develops, and produces x-ray and gamma-ray imaging, and radiation detection products for medical, security screening, and nuclear markets in the United Kingdom, North America, Asia, Europe, and Australasia. The company’s nuclear detection products include Kromek GR1, a gamma ray spectrometer; GR1-A, a USB-powered gamma spectrometer; SIGMA, a technology platform of scintillator products; TN15, a sensitivity thermal neutron detector; RadAngel, a personal radiation detector; MultiSpect spectrometry software; and Quant for GR1, a solution for measuring the activity of radionuclides. Its nuclear detection products also comprise RadAngel for Schools, a portable gamma-ray ...
Thomas Wright Way
Sedgefield, TS21 3FD
Founded in 2003
Kromek Group PLC Announces Board Changes
Sep 28 15
Kromek Group PLC announced that Sir Peter Williams CBE has been appointed as a Non-Executive Director of the company with immediate effect and as the Chairman of the Board of Directors with effect from the conclusion of the company's Annual General Meeting to be held in October 2015. Mr. Lawrence Kinet, who has held the position of Interim Chairman since 17 April 2015, will resume his role as Non-Executive Director of the company. WIlliam is currently Chairman of the Daiwa Anglo Japanese Foundation.
Lawrence Kinet Assumes the Role of Chairman of Kromek Group plc
Jul 30 15
On 17 April 2015, Lawrence Kinet was appointed Interim Chairman of Kromek Group plc. As of 29 July 2015, Mr. Kinet assumed the title of Chairman of the Company to provide stability and oversight to the executive management team and to assist in the recruitment process.
Kromek Group plc Reports Audited Consolidated Earnings Results for the Year Ended April 30, 2015
Jul 30 15
Kromek Group plc reported audited consolidated earnings results for the year ended April 30, 2015. For the year, the company reported revenue of GBP 8,101,000 compared to GBP 5,972,000 for the same period last year. Operating loss of GBP 3,064,000 compared to GBP 3,780,000 for the same period last year. Loss before tax of GBP 3,135,000 compared to GBP 4,295,000 for the same period last year. Loss for the period from continuing operations was GBP 2,146,000 or 0.02 basic and diluted loss per share compared to GBP 3,189,000 or 0.05 basic and diluted loss per share for the same period last year. Adjusted basic and diluted loss was 2 pence per share compared to loss of 5 pence per share, due to the Company having losses in each of the two years. Net cash used in operating activities was GBP 2,361,000 compared to GBP 2,218,000 for the same period last year. Purchase of property, plant and equipment was GBP 2,558,000 compared to GBP 187,000 a year ago. Purchases of patents and trademarks were GBP 368,000 compared to GBP 567,000 a year ago. LBITDA was GBP 1,680,000 compared to GBP 2,483,000 a year ago. Adjusted EBITDA was GBP 1,557,000 compared to GBP 3,007,000 a year ago.